Key Takeaways How the Decision Affects NVO's Competitive Edge in Obesity Novo Nordisk had signed the partnership agreement with HIMS in late April. Through the deal, the company was also trying to grow its obesity market share by boosting sales through increased patient access to Wegovy. NVO faces intense competition from Eli Lilly (LLY) , which markets its tirzepatide medicines, Mounjaro (diabetes) and Zepbound (obesity). Despite being on the market for less than three years, Lilly's Mounjaro and Zepbound ...

Amgen, by the way, also dropping almost 6% today after disappointing results for its once monthly weight loss shot. Maritide patients without type two diabetes losing an average of 20% of their body weight after one year. But the company reporting a high rate of side effects and discontinuations.It plans to adjust its dosing schedule in a phase three trial. For more on the obesity drug race, Jared Holles joins us here on set. He is a healthcare sector strategist at Missuo.Jared, great to have you with us. u ...

SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced the debut of its “Anatomy of Progress” nimacimab development update video series and availability of presentations related to the development of its anti-obesity drug, nimacimab, presented in multiple forums at the American Diabetes Association’s (ADA) 85th Scientific ...

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing weight loss interventions1When adhering to treatment, weight loss of ≥5%, ≥20%, ≥25%, and ≥30% was observed in 97.6%, 60.2%, 40.4% and 23.1% of patients respectively at 68 weeks1*The REDEFINE clinical programme is ongoing to further investigate efficacy and safety of CagriSema, including recently initiated REDEFINE 112 Bagsværd, ...

MariTide is the First Monthly or Less Frequently Dosed Peptide-Antibody Conjugate Being Investigated for the Treatment of Obesity and Type 2 Diabetes THOUSAND OAKS, Calif., June 18, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study for MariTide (maridebart cafraglutide, formerly AMG 133) in patients living with obesity, with and without Type 2 diabetes, will be presented along with new data from the Phase 3 FOURIER study of Repatha® (evolocumab) in cardio ...

Flash | 12 Jun 2025 08:08:06 ET │ 9 pages China Pharmaceuticals Catalysts ahead: Chinese companies in ADA 2025 CITI'S TAKE The American Diabetes Association (ADA) meeting (6/20-6/23; Chicago) will happen next week, and we summarize the expected presentations from the China companies due to attend. Innovent will likely present mazdutide DREAMS-1 Ph3 study for T2D and the preclinical data for the GLP-1/GIP/GCG/PCSK9 candidate. Oral GLP-1 data including ASC30 (Ph1a), HDM1002(Ph1b) and RGT-075 (Ph2a), as well a ...

Eli Lilly & Co. LLY may be down over 8% in the past month and nearly 5% over the past five days, but JPMorgan analyst Chris Schott isn't backing off. In fact, he's doubling down.Zepbound's Momentum Keeps Eli Lilly In The LeadWith Zepbound continuing to dominate the GLP-1 obesity category and new catalysts on the horizon, JPMorgan sees Eli Lilly as still one of the top picks in the sector.Prescriptions for both Zepbound and Mounjaro are running ahead of expectations in the second quarter, positioning Eli Lil ...

Imagine [Music] you're driving a car. Your body is that car. And the fuel you put in is the food you eat. What happens if you put the wrong fuel in the car.The car doesn't work right. it gets slower and maybe it even breaks down. Well, the same thing happens when we as teens don't fuel our bodies with the right nutrition.million. That's the number of teens and adolescents that were affected by obesity in 2022. That is a big and scary number.In fact, that's the entire population of the US plus 50 million mor ...

Key Takeaways Novo Nordisk will move amycretin into phase III trials for weight management starting in Q1 2026. The decision follows phase II feedback from regulators on both subcutaneous and oral amycretin. Amycretin aims to offer a long-acting, convenient option for obesity and type 2 diabetes treatment.Novo Nordisk (NVO) announced plans to advance amycretin, for weight management, into late-stage development. Amycretin is being developed for subcutaneous and oral administration.Shares of this Denmark-b ...

Structure Therapeutics (GPCR) FY Conference June 11, 2025 10:40 AM ET Speaker0 Following session is not open to the press. Speaker1 Perfect. Thanks, everyone, who's joining us here at the Goldman Sachs Annual Healthcare Conference. Thrilled to have Ray Stevens from Structured Therapeutics here to join us. Maybe you could just start with a quick overview of the business. I would love to kind of get started there, then we'll dig in. Speaker2 Absolutely, Corinne. So Structured Therapeutics is really built arou ...